Streetbeat News

Products Services

MOBQ

Mobiquity Technologies, Inc. (NASDAQ:MOBQ) has announced enhancements to its proprietary ElecTech and ElecAlytics platforms. The new features utilize heuristic models and US districting data to facilitate superior ad curation. The integration enables Mobiquity's AI engines to create hyper-segmented and personalized advertisements. The decision to integrate districting data highlights Mobiquity's commitment to optimizing localized targeting.

Portfolio Pulse from Happy Mohamed

July 05, 2023 | 12:08 pm

PSTX

Poseida Therapeutics, Inc. (NASDAQ:PSTX) has received FDA clearance for its Investigational New Drug (IND) application for P-CD19CD20-ALLO1, a dual CAR-T cell therapy for B-cell malignancies. This is the first FDA IND clearance of an allogeneic dual CAR-T therapy targeting CD19 and CD20. The therapy is being developed in partnership with Roche and will be evaluated in a Phase 1 study involving up to 70 adult patients.

Portfolio Pulse from Happy Mohamed

July 05, 2023 | 12:06 pm

MDLZ

Mondelez International, Inc. (NASDAQ:MDLZ) has issued a voluntary recall of two varieties of belVita Breakfast Sandwich products in the U.S. due to potential peanut contamination. The recall was discovered during an internal manufacturing inspection and is being conducted with the knowledge of the U.S. Food and Drug Administration. No other products or markets are affected by the recall. MDLZ shares are trading lower by 0.14% at $73.41 in premarket.

Portfolio Pulse from Shivani Kumaresan

July 05, 2023 | 12:06 pm

NKLA

Nikola Corporation (NASDAQ:NKLA) reported Q2 vehicle production and deliveries, with wholesale of 45 trucks and retail of 66 trucks. The company doubled its retail sales compared to Q1 and is planning to introduce a hydrogen fuel cell electric truck in Q3. Full financial results will be announced on August 4, 2023.

Portfolio Pulse from Happy Mohamed

July 05, 2023 | 12:05 pm

ABBV

JNJ

PTGX

Protagonist Therapeutics Inc (PTGX) announced positive results from the Phase 2b FRONTIER 1 trial of JNJ-2113, a psoriasis treatment developed by Janssen Biotech, a unit of Johnson & Johnson (JNJ). The drug hit its primary and secondary endpoints, showing significant improvements in skin lesions. However, it fell short of rival treatment Skyrizi, commercialized by AbbVie Inc (ABBV), in terms of PASI 90 score. PTGX shares are up 3.41% premarket.

Portfolio Pulse from Vandana Singh

July 05, 2023 | 11:33 am

CGTX

Cognition Therapeutics has announced the activation of the first clinical trial site for the Phase 2 START study of CT1812 in adults with early Alzheimer's disease. The site can now begin recruiting participants for the 540-patient study.

Portfolio Pulse from Benzinga Newsdesk

July 05, 2023 | 11:33 am

EWG

INTC

SOXX

Germany's Finance Minister Olaf Scholz has indicated that there are other chip projects in the works by German and other companies. The specific companies involved were not mentioned in the article.

Portfolio Pulse from Charles Gross

July 05, 2023 | 11:29 am

DXCM

DexCom, Inc.'s (NASDAQ:DXCM) Dexcom G7 Continuous Glucose Monitoring System has been approved by Health Canada. The device can warn of high or low glucose levels and help avoid hypoglycemic events. The approval gives Canadians access to a technology that reduces hospitalizations and emergency room visits due to hypoglycemia by up to 42%. The product is expected to be launched in Canada by the end of 2023.

Portfolio Pulse from Nabaparna Bhattacharya

July 05, 2023 | 11:16 am

TSLA

Tesla, Inc. (NASDAQ:TSLA) has reduced prices of its Model 3 and Y EVs in Japan by low single-digit percentages, continuing its aggressive pricing strategy into Q3. This follows Tesla's Q2 deliveries outperformance, partly attributed to price cuts and promotional measures. However, this move may stir investor anxiety concerning demand and margins ahead of the company’s earnings report due on July 19. In premarket trading, Tesla stock was down 0.60% at $278.14.

Portfolio Pulse from Shanthi Rexaline

July 05, 2023 | 11:15 am

CCCC

The FDA has cleared C4 Therapeutics' Investigational New Drug Application for CFT8919, a treatment for non-small cell lung cancer. C4T plans to initiate trials outside Greater China after Betta Pharmaceuticals concludes its Phase 1 dose escalation study in the region.

Portfolio Pulse from Benzinga Newsdesk

July 05, 2023 | 11:03 am